TPST logo

Tempest Therapeutics (TPST) EBITDA

Annual EBITDA

-$27.66 M
+$5.79 M+17.31%

December 31, 2023


Summary


Performance

TPST EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTPSTprofitabilitymetrics:

Quarterly EBITDA

-$10.13 M
-$1.09 M-12.02%

September 30, 2024


Summary


Performance

TPST Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTPSTprofitabilitymetrics:

TTM EBITDA

-$33.65 M
-$3.81 M-12.75%

September 30, 2024


Summary


Performance

TPST TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTPSTprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

TPST EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+17.3%-60.2%-15.7%
3 y3 years-46.6%-60.2%-15.7%
5 y5 years-46.6%-60.2%-15.7%

TPST EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-3.8%+17.3%-60.2%at low-26.3%at low
5 y5-year-46.6%+17.3%-139.1%at low-543.5%at low
alltimeall time-46.6%+17.3%-139.1%at low-543.5%at low

Tempest Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$10.13 M(+12.0%)
-$33.65 M(+12.8%)
Jun 2024
-
-$9.04 M(+21.4%)
-$29.84 M(+6.8%)
Mar 2024
-
-$7.45 M(+6.0%)
-$27.94 M(+1.0%)
Dec 2023
-$27.66 M(-17.3%)
-$7.03 M(+11.1%)
-$27.66 M(-4.9%)
Sep 2023
-
-$6.33 M(-11.5%)
-$29.09 M(-6.5%)
Jun 2023
-
-$7.14 M(-0.3%)
-$31.12 M(-4.4%)
Mar 2023
-
-$7.17 M(-15.2%)
-$32.57 M(-2.6%)
Dec 2022
-$33.45 M
-$8.45 M(+1.2%)
-$33.45 M(+3.4%)
Sep 2022
-
-$8.36 M(-2.7%)
-$32.34 M(+2.5%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$8.59 M(+6.7%)
-$31.55 M(+6.4%)
Mar 2022
-
-$8.05 M(+9.7%)
-$29.65 M(+11.3%)
Dec 2021
-$26.65 M(+41.2%)
-$7.34 M(-3.0%)
-$26.65 M(+13.2%)
Sep 2021
-
-$7.57 M(+13.0%)
-$23.54 M(+10.4%)
Jun 2021
-
-$6.70 M(+32.7%)
-$21.33 M(+7.4%)
Mar 2021
-
-$5.05 M(+19.1%)
-$19.86 M(+34.1%)
Dec 2020
-$18.87 M
-$4.24 M(-20.8%)
-$14.81 M(+40.0%)
Sep 2020
-
-$5.35 M(+2.3%)
-$10.58 M(+102.3%)
Jun 2020
-
-$5.23 M
-$5.23 M

FAQ

  • What is Tempest Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Tempest Therapeutics?
  • What is Tempest Therapeutics annual EBITDA year-on-year change?
  • What is Tempest Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Tempest Therapeutics?
  • What is Tempest Therapeutics quarterly EBITDA year-on-year change?
  • What is Tempest Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Tempest Therapeutics?
  • What is Tempest Therapeutics TTM EBITDA year-on-year change?

What is Tempest Therapeutics annual EBITDA?

The current annual EBITDA of TPST is -$27.66 M

What is the all time high annual EBITDA for Tempest Therapeutics?

Tempest Therapeutics all-time high annual EBITDA is -$18.87 M

What is Tempest Therapeutics annual EBITDA year-on-year change?

Over the past year, TPST annual EBITDA has changed by +$5.79 M (+17.31%)

What is Tempest Therapeutics quarterly EBITDA?

The current quarterly EBITDA of TPST is -$10.13 M

What is the all time high quarterly EBITDA for Tempest Therapeutics?

Tempest Therapeutics all-time high quarterly EBITDA is -$4.24 M

What is Tempest Therapeutics quarterly EBITDA year-on-year change?

Over the past year, TPST quarterly EBITDA has changed by -$3.81 M (-60.16%)

What is Tempest Therapeutics TTM EBITDA?

The current TTM EBITDA of TPST is -$33.65 M

What is the all time high TTM EBITDA for Tempest Therapeutics?

Tempest Therapeutics all-time high TTM EBITDA is -$5.23 M

What is Tempest Therapeutics TTM EBITDA year-on-year change?

Over the past year, TPST TTM EBITDA has changed by -$4.56 M (-15.67%)